What We Know from the Latest PEPFAR Data: Analysis of FY 2025 Quarter 4 Results Authors: Jennifer Kates, Anna Rouw, and Allyala Nandakumar Published: Apr 23, 2026

https://www.kff.org/global-health-policy/what-we-know-from-the-latest-pepfar-data-analysis-of-fy-2025-quarter-4-results/?utm_campaign=KFF-Global-Health-Policy&utm_medium=email&_hsenc=p2ANqtz--urifhw4coBt7K3GoeVKR2AGYnXKoe9l3SDl4KrdnBJC_E_oTY6S7oIdxNUVZEv-lYKMx_S6RVCRsaXUTB_bHP3p_8nQ&_hsmi=415415978&utm_content=415415978&utm_source=hs_email What We Know from the Latest PEPFAR Data KFF analysis of newly released data from the President’s Emergency Plan for AIDS Relief (PEPFAR) reveals mixed outcomes on key program-level metrics. For example, while the total number of people on antiretroviral therapy (ART) remained stable in FY 2025 Q4 (20.3 million) compared to Q4 2024 (20.4 million), the number of newly enrolled patients on ART fell by 16% to approximately 389,000 — one of the steepest year-to-year quarter declines recorded in five years. Among other outcomes, the brief notes significant declines in prevention services like pre-exposure prophylaxis (PrEP) and for the Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe (DREAMS) program for teen girls and young women. The analysis, based on data released by the State Department on April 17, compares results from July to September 2025 (FY 2025 Q4) against the same period in five preceding years. The data’s release marks the first program-level PEPFAR data made available since the Trump administration significantly reorganized and scaled back U.S. global health programming and released a new “America First Global Health Strategy” last year. The future of transparent PEPFAR data monitoring and reporting remains uncertain, however, and it will be difficult to track the impact of PEPFAR changes going forward without them. Contact: Mikhaila Richards | 202.654.1328 | MRichards@kff.org